Revolutionizing Patient Care
Accelerating Biopharmaceutical Innovation
TrueBinding is optimizing patient care through its revolutionary pipeline of monoclonal antibody therapeutics, providing targeted treatments for a diverse range of diseases and medical conditions. By harnessing the power of our platform technology, we rapidly develop and deliver highly specific and effective monoclonal antibodies, ushering in a new era of precision medicine that holds the promise of improved patient outcomes and enhanced therapeutic options.
Accelerating Biopharmaceutical Innovation
TrueBinding's contract development and manufacturing services offer unparalleled benefits for clients in the biopharmaceutical industry. By leveraging our advanced technology and expertise, our teams can accelerate the development process, ensuring rapid and efficient production of high-quality monoclonal antibodies, ultimately enabling clients to bring their innovative therapies to market faster and more cost-effectively.
TB006 Expanded
Access Program
Granting access to investigational medications, the Expanded Access Program (EAP) for TB006 offers a compassionate approach to providing potential benefits to patients who have exhausted all other alternatives combating Alzheimer’s Disease.
Completion of Phase 1b/2a Clinical Trial for Alzheimer's Disease
Topline data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients, indicating the potential of slowing or reducing clinical decline. Key secondary endpoints were consistent with the primary findings that TB006 improved cognition and function in patients
TB006 for Alzheimer’s Disease
A revolutionary new drug with the potential to reverse the progression of the disease, as demonstrated in recent clinical trials.
TB006 for Stroke
A drug in early clinical trials, believed to show a positive impact on stroke patients.
TB006, a humanized monoclonal antibody targeting Galectin-3, is a potentially revolutionary drug for Alzheimer’s Disease treatment
TB006 could reverse AD progress by blocking Gal-3, the root cause of Abeta oligomerization and plaque formation
Alzheimer's Disease is a brain disorder that starts slowly, then gradually worsens and robs people of their memory as well as other cognitive abilities that are required for daily living. It leads to the most common form of dementia and is characterized by abnormal clumping of amyloid beta (Abeta) proteins into toxic plaques. These plaques deposit in the brain, clogging communication between neurons, which results in symptoms of cognition defects.
In addition to these plaques, there is another protein involved called Galectin-3 (Gal3), which is found at abnormally high levels in the brains of Alzheimer’s Disease patients. Gal3 binds to Abeta, and acts as a glue, causing Abeta to bind to itself and form toxic plaques. The Abeta plaques then deposit onto neurons, blocking communication signals between neurons and leading to cognition defect symptoms in Alzheimer’s Disease patients.
TB006 is a revolutionary new drug developed to treat Alzheimer’s Disease. By binding to Gal3, the TB006 drug prevents Gal3 from acting as a glue. This reduces and dissolves the toxic Abeta plaques in the brain, which allows neurons to communicate again, thus resulting in the cognition improvement.
Can Advanced Functional Medicine Help you?
Call Our Team Today to Schedule Your Private Consultation.
​
Experience the wonderful difference that Advanced Functional Medicine
with Dr. Frank Tortorice can make in your life!
If you’re curious about Functional Medicine or would like to learn about our services, call today!